Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency
Wehr, Claudia; Gennery, Andrew R.; Lindemans, Caroline; Schulz, Ansgar; Hoenig, Manfred; Marks, Reinhard; Recher, Mike; Gruhn, Bernd; Holbro, Andreas; Heijnen, Ingmar; Meyer, Deborah; Grigoleit, Goetz; Einsele, Hermann; Baumann, Ulrich; Witte, Thorsten; Sykora, Karl-Walter; Goldacker, Sigune; Regairaz, Lorena; Aksoylar, Serap; Ardeniz, Omur; Zecca, Marco; Zdziarski, Przemyslaw; Meyts, Isabelle; Matthes-Martin, Susanne; Imai, Kohsuke; Kamae, Chikako; Fielding, Adele; Seneviratne, Suranjith; Mahlaoui, Nizar; Slatter, Mary A.; Gungor, Tayfun; Arkwright, Peter D.; van Montfrans, JM; Sullivan, Kathleen E.; Grimbacher, Bodo; Cant, Andrew; Peter, Hans-Hartmut; Finke, Juergen; Gaspar, H. Bobby; Warnatz, Klaus; Rizzi, Marta; European Soc Blood Marrow; European Soc Immunodeficiency
(2015) Journal of Allergy and Clinical Immunology, volume 135, issue 4, pp. 988 - 997.e6
(Article)
Abstract
Background: Common variable immunodeficiency (CVID) is usually well controlled with immunoglobulin substitution and immunomodulatory drugs. A subgroup of patients has a complicated disease course with high mortality. For these patients, investigation of more invasive, potentially curative treatments, such as allogeneic hematopoietic stem cell transplantation (HSCT), is warranted. Objective: We sought
... read more
to define the outcomes of HSCT for patients with CVID. Methods: Retrospective data were collected from 14 centers worldwide on patients with CVID receiving HSCT between 1993 and 2012. Results: Twenty-five patients with CVID, which was defined according to international criteria, aged 8 to 50 years at the time of transplantation were included in the study. The indication for HSCT was immunologic dysregulation in the majority of patients. The overall survival rate was 48%, and the survival rate for patients undergoing transplantation for lymphoma was 83%. The major causes of death were treatment-refractory graft-versus-host disease accompanied by poor immune reconstitution and infectious complications. Immunoglobulin substitution was stopped in 50% of surviving patients. In 92% of surviving patients, the condition constituting the indication for HSCT resolved. Conclusion: This multicenter study demonstrated that HSCT in patients with CVID was beneficial in most surviving patients; however, there was a high mortality associated with the procedure. Therefore this therapeutic approach should only be considered in carefully selected patients in whom there has been extensive characterization of the immunologic and/or genetic defect underlying the CVID diagnosis. Criteria for patient selection, refinement of the transplantation protocol, and timing are needed for an improved outcome.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Common variable immunodeficiency, hypogammaglobulinemia, hematopoietic stem cell transplantation, immunologic reconstitution, immunoglobulin substitution/replacement, outcome, mortality, survival, BONE-MARROW-TRANSPLANTATION, SEVERE APLASTIC-ANEMIA, VERSUS-HOST-DISEASE, B-CELL, EUROPEAN GROUP, WORKING PARTY, ACUTE GVHD, DISORDERS, BLOOD, CLASSIFICATION, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
ISSN: 0091-6749
Publisher: Mosby Inc.
(Peer reviewed)